Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s379. https://doi.org/10.25251/skin.8.supp.379